Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?

Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?

Bibliografski detalji
Glavni autori:	Banerjee, R, Kelly, M, Wilman, H, Wright, T, Neubauer, S
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2018

Slični predmeti

Editorial: Mechanistic insight and therapeutic potential for the management of non-alcoholic steatohepatitis (NASH)
od: Umashanker Navik, i dr.
Izdano: (2024-11-01)

REVIEW PAPER<br>Non-alcoholic steatohepatitis (NASH)
od: János Fehér, i dr.
Izdano: (2005-04-01)

Corrigendum: Editorial: Mechanistic insight and therapeutic potential for the management of non-alcoholic steatohepatitis (NASH)
od: Umashanker Navik, i dr.
Izdano: (2024-12-01)

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
od: Jin Ha Lee, i dr.
Izdano: (2020-10-01)

Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An update
od: Sorina Cezara Coste, i dr.
Izdano: (2019-05-01)

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
od: Xiaohan Xu, i dr.
Izdano: (2022-08-01)

Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
od: Jessica Min-DeBartolo, i dr.
Izdano: (2019-01-01)

Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
od: Xinzhi Li, i dr.
Izdano: (2022-08-01)

Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
od: Amedeo Lonardo, i dr.
Izdano: (2024-01-01)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
od: Savneet Kaur, i dr.
Izdano: (2019-10-01)

An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials
od: Wei-Qiang Leow, i dr.
Izdano: (2020-08-01)

Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF)
od: Yasemin H. Balaban, i dr.
Izdano: (2006-04-01)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
od: Hannah K. Drescher, i dr.
Izdano: (2019-06-01)

A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis
od: Dennis, A, i dr.
Izdano: (2020)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
od: J.T. Stefano, i dr.
Izdano: (2015-02-01)

Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH).
od: Jianfeng Cheng, i dr.
Izdano: (2012-01-01)

Oyster extracts attenuate pathological changes in non-alcoholic steatohepatitis (NASH) mouse model
od: Mitsugu Watanabe, i dr.
Izdano: (2016-01-01)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
od: J.T. Stefano, i dr.
Izdano: (2015-05-01)

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
od: Christian L. Horn, i dr.
Izdano: (2022-01-01)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
od: Elliot B. Tapper, i dr.
Izdano: (2023-04-01)

Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) – A single arm clinical trial.
od: Shruti Tarapure, i dr.
Izdano: (2021-01-01)

A classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy
od: Yu, Yang, i dr.
Izdano: (2018)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
od: Jérôme Eeckhoute
Izdano: (2022-08-01)

Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH)
od: Orla Doyle, i dr.
Izdano: (2022-02-01)

Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives
od: Torre E, i dr.
Izdano: (2022-09-01)

Placental extract ameliorates non-alcoholic steatohepatitis (NASH) by exerting protective effects on endothelial cells
od: Akihiro Yamauchi, i dr.
Izdano: (2017-09-01)

Therapeutic approaches for non-alcoholic steatohepatitis
od: Luc F. Van Gaal, i dr.
Izdano: (2021-09-01)

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
od: D.N. Amarapurkar, i dr.
Izdano: (2006-01-01)

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
od: Yi-wen Shi, i dr.
Izdano: (2023-02-01)

Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design
od: Xianwen Chen, i dr.
Izdano: (2023-05-01)

Development of a classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy
od: Yan, Jie, i dr.
Izdano: (2019)

The role of indoleamine 2,3-dioxygenase (IDO) in the pathogenesis of non-alcoholic steatohepatitis (NASH) and atherosclerosis as comorbidities
od: Arora, A, i dr.
Izdano: (2021)

Hepatocellular carcinoma in a non-B non-C non-alcoholic steatohepatitis (NBNC-NASH HCC)
od: M. F., Fairudz, i dr.
Izdano: (2010)

Vitamin E + Ursodeoxycholic Acid (UDCA) Versus Vitamin E for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
od: Sayyed Moayyed Alavian, i dr.
Izdano: (2010-11-01)

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints
od: Naim Alkhouri, i dr.
Izdano: (2019-12-01)

Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
od: Mah I Kan Changez, i dr.
Izdano: (2023-09-01)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
od: Ozlem Kutlu, i dr.
Izdano: (2018-01-01)

Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis
od: Dennis, A, i dr.
Izdano: (2021)

Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?
od: Tariq, Z, i dr.
Izdano: (2014)

Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?
od: Tariq, Z, i dr.
Izdano: (2014)